Business News Today Article: Myopia drug breakthrough: Sydnexis’ SYD-101 approved in Europe, Ryjunea launch next
Sydnexis, a privately held U.S. biopharmaceutical company, secured a critical regulatory victory on June 5, 2025, with the European Commission granting marketing authorization for SYD-101, its proprietary low-dose atropine eye drop.
Valuation expectations are rising. If SYD-101 succeeds in both the EU and U.S., Sydnexis could command a biotech valuation in the range of $1.5 billion to $2 billion, based on typical pre-commercial revenue multiples. Investor interest is expected to accelerate in Q4 as FDA decision timelines approach.